ERBB2 and breast carcinoma: Even though the expression of ZFX variant 5 was higher in the triple-negative and luminal A subtypes rather than HER2 type and luminal B subtypes, there is not significant association between ZFX variant 5 expression levels and breast cancer subtypes (Fig. 4A).